Traws Pharma, Inc. TRAW 深 沪
等待开盘 05-21 09:30:00 美东时间
1.62
+0.030
+1.89%
华盛通- 最 高1.72
- 今 开1.60
- 成交量 93.62万股
- 最 低 1.55
- 昨 收 1.59
- 总市值 2454.41万
- 52周最高 3.265
- 市盈率 静 1.48
- 换手率 6.18%
- 52周最低 0.995
- 委 比 10.15%
- 总股本 1515.07万
- 历史最高 1751062.50
- 量 比 0.86
- 振 幅 10.69%
- 历史最低 0.97
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Reiterates Buy on Traws Pharma, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Buy and maintains $8 price target.
05-20 18:45
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 66.46 percent increase over losses of $(1.58) per share from the
05-15 19:09
Traws Pharma Announces Plans To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infection
Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral
05-08 19:32
Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 85.8 percent increase over losses of $(5.00) per share from the
04-16 04:25
Traws Pharma Prices $10M PIPE At $1.673/Share For 5.98M Shares, Issues Warrants For Up To 29.9M Shares With $50M Additional Upside Potential
Entry into a Material Definitive Agreement PIPE Securities Purchase Agreement On April 15, 2026, Traws Pharma, Inc. (the "Company") announced the pricing of an offering (the "Private Placement") of an aggregate
04-15 20:17
Traws Pharma Completed Clinical Analysis Of Its 90-patient, Open-label Phase 2 Study Of Ratutrelvir Versus Paxlovid For Mild-to-moderate Covid-19
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were
02-19 20:36
Traws Pharma Completes Enrollment In Ongoing 90-Patient, Open-Label Phase 2 Study Of Ratutrelvir, Investigational Oral, Ritonavir-Free Mpro/3CL Protease Inhibitor, Versus PAXLOVID, In COVID-19 Patients
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated
01-26 21:32
Traws Pharma shares are trading higher after the company announced the filing of a U.S. IND application with FDA for tivoxavir marboxil to treat influenza.
Traws Pharma shares are trading higher after the company announced the filing o...
01-14 03:01
Traws Pharma's Interim Data For Ratutrelvir Demonstrated A Differentiated Clinical Profile In Pre-specified Interim Analysis Of An Ongoing Open-label Phase 2 Study For Mild-to-moderate Covid-19, Final Data Analysis Expected In January 2026
The study was designed as an active-controlled comparator trial versus PAXLOVID™ (nirmatrelvir/ritonavir) and evaluated patient-reported symptom outcomes, safety, and real-world usability. A separate treatment arm
2025-12-17 19:02
